Page last updated: 2024-09-04

fidarestat and Cardiotoxicity

fidarestat has been researched along with Cardiotoxicity in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awasthi, S; Pal, PB; Ramana, KV; Sonowal, H; Srivastava, SK; Wen, JJ	1

Other Studies

1 other study(ies) available for fidarestat and Cardiotoxicity

Article	Year
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity. Scientific reports, 2017, 06-09, Volume: 7, Issue:1 Topics: Aldehyde Reductase; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiotoxicity; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazolidines; Mice; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Xenograft Model Antitumor Assays	2017

Article

Year

Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity.

Scientific reports, 2017, 06-09, Volume: 7, Issue:1

Topics: Aldehyde Reductase; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cardiotoxicity; Cell Proliferation; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazolidines; Mice; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Xenograft Model Antitumor Assays

2017